NCT05350072: An ongoing trial by Novartis Pharmaceuticals
This trial is ongoing. It must report results 4 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05350072 |
|---|---|
| Title | A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 28, 2022 |
| Completion date | May 7, 2025 |
| Required reporting date | May 7, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |